Beijing Biotech
Privately held: no public share price
Assets
(5 total)
5Total Assets
0Approved
0Phase 3 / Filed
5Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | CD19Cell therapy | Systemic Lupus Erythematosus | |
| Phase 1/2 | BCMA × CD19Cell therapy | Multiple Myeloma | |
| Phase 1/2 | BCMA, CD38 (dual-target)Cell therapy | Multiple Myeloma | |
| Phase 1/2 | BCMA / GPRC5DCell therapy | Multiple Myeloma | |
| Phase 1/2 | Dual-antigen combinations: MSLN+EGFR, MSLN+HER2/ERBB2Cell therapy | Non-Small Cell Lung Cancer |
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (10)
February 2027 (2)
Est. primary completion 2027-02-14 · NCT07467863 · CT.gov ↗
What to watch
Dual-target Car-nk CellsPhase 1/2Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)
Est. primary completion 2027-02-14 · NCT07486089 · CT.gov ↗
What to watch
March 2027 (7)
Est. primary completion 2027-03-14 · NCT07500220 · CT.gov ↗
What to watch
Dual-target Car-nk CellsPhase 1/2Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
Est. primary completion 2027-03-14 · NCT07510802 · CT.gov ↗
What to watch
Dual-target Car-nk CellsPhase 1/2Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
Est. primary completion 2027-03-14 · NCT07589543 · CT.gov ↗
What to watch
Dual-target Car-nk CellsPhase 1/2Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC
Est. primary completion 2027-03-14 · NCT07617805 · CT.gov ↗
What to watch
Est. primary completion 2027-03-14 · NCT07641023 · CT.gov ↗
What to watch
Beijing Biotech BCMA/CD19 dual-target CAR-T + Beijing Biotech BCMA/CD38 dual-target CAR-T + Beijing Biotech BCMA/GPRC5D dual-target CAR-TPhase 1/2Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL …
Est. primary completion 2027-03-14 · NCT07523555 · CT.gov ↗
What to watch
Est. primary completion 2027-03-14 · NCT07523542 · CT.gov ↗
What to watch
December 2027 (1)
Est. primary completion 2027-12-21 · NCT07462650 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.